Correct Answer: B. Cyclophosphamide
Cyclophosphamide is a nitrogen mustard alkylating agent widely used in chemotherapy for lymphomas, leukemias, and autoimmune diseases in Indian clinical practice. Its metabolite acrolein is directly toxic to the urothelium and causes hemorrhagic cystitis acutely; chronically, it leads to bladder fibrosis, strictures, and urothelial carcinoma (squamous cell carcinoma most common, followed by adenocarcinoma). The risk increases with cumulative dose (>20 g/m²) and prolonged exposure. In Indian cancer centers, cyclophosphamide-induced bladder cancer is a recognized late complication in long-term survivors of lymphomas and leukemias treated in the 1980s–2000s. The mechanism involves direct DNA alkylation and chronic inflammation. Mesna (a uroprotective agent) reduces but does not eliminate this risk. The latency period is typically 5–10 years post-exposure, making it a critical surveillance point in follow-up of Indian cancer survivors. This is the only chemotherapy agent among the options with established bladder carcinogenicity.
Why the other options are wrong
A. Cisplatin — Cisplatin is a platinum-based alkylating agent used in testicular cancer, ovarian cancer, and bladder cancer chemotherapy in India. While it causes acute nephrotoxicity and ototoxicity, it is not associated with secondary bladder carcinoma. Unlike cyclophosphamide, cisplatin does not produce urotoxic metabolites. NBE may pair cisplatin with bladder toxicity to trap students who confuse acute chemotherapy toxicity with carcinogenicity. C. Taxane — Taxanes (paclitaxel, docetaxel) are microtubule-stabilizing agents used in breast, ovarian, and lung cancers in Indian oncology practice. Their toxicity profile includes peripheral neuropathy, myelosuppression, and hypersensitivity reactions—not bladder carcinogenicity. No mechanistic basis exists for urothelial malignant transformation with taxanes. D. Tamoxifen — Tamoxifen is a selective estrogen receptor modulator used for breast cancer in Indian women. While it increases endometrial carcinoma risk (well-established), it is not associated with bladder cancer. This option may trap students who recall tamoxifen's carcinogenic potential but misattribute it to the bladder rather than the endometrium.
High-Yield Facts
- Cyclophosphamide metabolite acrolein is the direct urotoxic agent causing hemorrhagic cystitis and chronic bladder carcinoma.
- Cumulative dose >20 g/m² of cyclophosphamide significantly increases bladder cancer risk in Indian cancer survivors.
- Latency period 5–10 years post-cyclophosphamide exposure; squamous cell carcinoma is the most common histology.
- Mesna (uroprotective agent) reduces acrolein-induced cystitis but does not eliminate carcinoma risk; adequate hydration and frequent voiding are essential.
- Cyclophosphamide-induced bladder cancer is a recognized late complication in Indian lymphoma and leukemia survivors treated decades ago.
Mnemonics
CYTO-BLADDER CYclophosphamide → TO → BLADDER cancer. Acrolein metabolite + chronic inflammation = urothelial malignancy. Chemotherapy Carcinogenicity (Indian DOCs) Cyclo (bladder), Tamox (endometrium), Alk agents (leukemia). Remember: Cyclophosphamide uniquely targets the bladder via acrolein.
NBE Trap
NBE pairs chemotherapy agents with acute toxicity (cisplatin nephrotoxicity, tamoxifen endometrial risk) to distract from cyclophosphamide's unique chronic bladder carcinogenicity. Students may confuse "bladder toxicity" (hemorrhagic cystitis) with "bladder cancer risk" and incorrectly choose cisplatin.
Clinical Pearl
In Indian cancer centers, long-term survivors of Hodgkin lymphoma and ALL treated with cyclophosphamide in the 1980s–1990s now present with bladder cancer in their 40s–50s. Regular urinalysis and cystoscopy screening are recommended for cumulative dose >20 g/m² to enable early detection.
_Reference: KD Tripathi Pharmacology Ch. 62 (Anticancer Drugs); Robbins Pathology Ch. 7 (Chemical Carcinogenesis)_